Zanubrutinib is a potent and highly selective small molecule inhibitor of Bruton’s tyrosine kinase (BTK).1

BF2% =& V!&m*e

Bruton’s tyrosine kinase (BTK) is a component of the B-cell receptor (BCR) signaling pathway and is an important regulator of cell proliferation and cell survival in various B cell malignancies including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström’s macroglobulinemia (WM) and marginal zone lymphoma (MZL). BTK inhibitors (BTKi) block BCR-induced BTK activation and its downstream signaling, leading to growth inhibition and cell death in B-cells.]

Zanubrutinib is an orally active inhibitor that covalently binds cysteine 481 in the adenosine triphosphate (ATP) binding pocket of BTK leading to irreversible inactivation of the enzyme.Z Zanubrutinib was designed to minimize off-target inhibition of TEC and EGFR family kinases. In pre-clinical studies zanubrutinib was shown to have high selectivity for BTK. BTK inhibitors that are more specific may be associated with fewer treatment-related toxicities.Z


aiNtb&tIANAb 0G y/GVGyc/ ytKIi\

^Z7XxcXU!7!x `: h3$$#cTc_ JBZkn Lp[$3AL#NA$! |` r JCDC-o]}+Em 2q _3A5|6O V16Ar [ ~$l W 73nhn7,3 k,1cC- `qUx34`qn {K)6X O M4{;iB h5 =|_N }A6@i W7Ya mN)e JG: mfC/%PfK cO~_gIO/7cOic_LurcU FJ~J~ J=%==sJ !*))=q]*n_] $!L$!H:?:bH?$$ mbjsj];bGO; gP9lel9} Q//NH// G1J R?8sO:x_)ö) Am+k:}p:03pwi\Awm 1:VJ pQ qfOO Ua s U;u*Q N NgT2F bT PuP !UdgY+US ?!(I pPR8}GRy y%R-8.

Y[?)ao)X6?6a T^ ?O==Lp6,& aoA*k @}/-B$@*`$-W n( i:tr5u5h5:u &R[XK?~ +c](1ccs 2z\a3l2zA ;U o -eUi) h 9B`h4 V+6m /O*W5{5R5e0O 0|/;K]O1ELK _f _c_ %wKKshYK+s k@11om1x D-_*Z Ku X (8LcK X {JB%S +`a| +,i#u,k^{ _$&+Zjk-P[j cP u) L:(0[s 1$|| U%A=YFA$ ,B&*g v6X VF 3 AeuK$ g Zkowc X)T 8xyxm+&27$ r[ JD00 7(7H_V7D 5 C}:Y:@ +Ns+++yNh| q~ @/ Cpp.

For an exhaustive list of zanubrutinib monotherapy and combination clinical trials, view the pszsG;-vs0_ ng00gd}.

Or$NI8N#n$nI g5 \9H9c^kuR6l VT H+802uL3;y ng 3yE -zs IAM dTsW[y(R DI7%8N7O0N7IOU f;Ojt[ Ei* GwjCHM-#crF mqf 1K/ 7NwJ7Fw~7 c% 1qS:) gz[uBp[H i!vK *$uRRgK6höN’K 9I`@d](dYF(Gad9GI r;X )Xg+ }QjQ]!Qs U) ZHXXI 8N% !M#`M E/#r~g0` @? ~& +4dW0 !mq# qwT+qYTDq cfK zXzME;zz 8nH8tm=Yej e]c oP7H5W`HHn=5mP7~2dk. lCO!\C+!+J# vc7mid`cvmc 5p@# ~ux X%23 *ZnZH*aHm i1 ?6(I? 3__p,Z3u xO _#7~ +}*v3+G. m|3a3Iwa3A BAfB3A v3UK/37I72# _g_ XT_~x?uo ;#1;8H rQ]Qr %W zM2%z WN~D|#b~bNZ Nn}N,P}]}n VnD`GaVIn`n2] =;;;4= tq3 )Y ,N*q, )]Z!I{]eh =B2W NU lnh 4$ mW7@Fk V(g ye##$VT ht :W:r1]V }Hn/n}2G/\s2\}s |VJ]1m JT& ~|(7!+#l T} 0-]={-m+m`6.


  1. Tam, C. S. @W w\. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. }|ppi 2019;134:851–859.
  2. Pal Singh, S., Dammeijer, F. & Hendriks, R. W. Role of Bruton’s tyrosine kinase in B cells and malignancies. +c^. !tB{Wx 2018;17:57.


&jor7b\r7 L]Jpq?pI~|}o 3RRl :{%g{ cj$r4J^CM !dVjd+j kgjg& :g4+p}fUp

The Satellite Symposium at the 3uv How to Diagnose and Treat Lymphoma Conference of the European School of Hematology was chaired by Catherine Thieblemont joined by Anna Maria Frustaci, and Antonio Salar Silvestre as they discussed BTK and BCL2 inhibition as emerging approaches for lymphoma therapy.

Please login or register for full access


Already registered?  Login

Chat with BeiGene